Fig. 3. Combination of selinexor and venetoclax decreases tumor growth and increases survival in a mouse multiple myeloma xenograft model.

Tumor volume measurements from mice randomized to receive treatment with vehicle, selinexor, venetoclax or the combination of selinexor and venetoclax (a). The combination-treated group showed a significant decrease in tumor volume when compared to the other groups (P = < 0.0001). Mice were treated with selinexor (5 mg/kg) three times per week, venetoclax (100 mg/kg) daily, or the combination of the drugs on the same dose and schedule. Both drugs were given by oral gavage and vehicle-treated mice were treated with both vehicles on the same schedule as the treated groups. The overall survival by Kaplan–Meier estimator is shown in (b). There was a significant increase in the survival of the combination-treated group when compared to the other groups (P = 0.0004). Log-rank test was used to compare survival.